
zzso a natural product, was studied as an zzso zzso with zzso zzso zzso in an escalating dose Phase I clinical zzso zzso was administered orally at doses from 300 zzso to 500 zzso daily zzso zzso The zzso was determined to be 500 zzso with moderate zzso and occasional zzso Side effects were mainly attributable to zzso rather than the study zzso A total of 18 patients were registered on study with only one patient determined to be intolerant of zzso due to zzso and zzso In this Phase I study four patients (3 breast, 1 zzso remained stable for greater than two cycles of zzso No complete or partial responses were seen in this zzso resistant population of patients with advanced zzso 

